Andrea Boutros, Assistant Professor at University of Genoa, shared a post on LinkedIn:
“Excited to share Part 1 of the MatchMEL study, now published in JCO Journals Precision Oncology!
We used Foundation Medicine comprehensive genomic profiling in 210 patients with advanced melanoma to characterise the molecular landscape of BRAF/NRAS wild-type disease, and understand clinical and pathological correlations.
Key findings:
- NF1 mutations in 43% of WT tumors – highest TMB subgroup (median 53 mut/Mb)
- High TMB significantly predicted longer PFS (26.8 vs 16.1 months, p<0.001)
- NF1-mutant melanoma: ORR 63%, 24-month PFS 58%
- Prior ICI exposure (adjuvant/neoadjuvant) = shorter PFS in the advanced setting
- Co-alterations in CDKN2A/B & PTEN enriched in high-TMB non-responders
These findings shaped the matched targeted therapy program in Part 2 of MatchMEL, guided by a Molecular Tumor Board.
Thank you to the incredible team at Melanoma Institute Australia and University of Sydney (Alexander Menzies, Georgina Long, James Wilmott, Carina Paola Cornejo Páramo, Serigne Lo, PhD, Monica Osorio, Janet McKeown), Università degli Studi di Genova․”
Title: Molecular Profiling and Matched Targeted Therapy for Patients With Advanced Melanoma: Results From Part 1 of the MatchMEL Study
Authors: Andrea Boutros, Matteo S. Carlino, Raja Chaganti, Maria Gonzalez, Serigne N. Lo, Ines Pires da Silva, Terence Wong, Janet McKeown, Andrew Colebatch, Robert V. Rawson, Paola Cornejo Páramo, Richard A. Scolyer, Helen Rizos, James S. Wilmott, Georgina V. Long, Alexander M. Menzies
Read the Full Article.
Other articles featuring Andrea Boutros on OncoDaily.